Athersys, Inc. (ATHX) Given Consensus Rating of “Strong Buy” by Analysts

Shares of Athersys, Inc. (NASDAQ:ATHX) have received an average broker rating score of 1.00 (Strong Buy) from the two brokers that cover the stock, Zacks Investment Research reports. Two investment analysts have rated the stock with a strong buy rating.

Brokers have set a 12-month consensus price objective of $8.00 for the company and are expecting that the company will post ($0.09) earnings per share for the current quarter, according to Zacks. Zacks has also assigned Athersys an industry rank of 58 out of 256 based on the ratings given to related companies.

Several research analysts have recently issued reports on the stock. BidaskClub upgraded shares of Athersys from a “sell” rating to a “hold” rating in a report on Wednesday, September 26th. Zacks Investment Research cut shares of Athersys from a “strong-buy” rating to a “hold” rating in a report on Tuesday, October 9th. Finally, ValuEngine cut shares of Athersys from a “buy” rating to a “hold” rating in a report on Thursday.

In other news, insider William Lehmann, Jr. sold 15,000 shares of the stock in a transaction that occurred on Tuesday, December 18th. The shares were sold at an average price of $1.73, for a total value of $25,950.00. Following the completion of the transaction, the insider now directly owns 493,062 shares in the company, valued at $852,997.26. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 18.60% of the company’s stock.

A number of hedge funds have recently added to or reduced their stakes in ATHX. Alps Advisors Inc. acquired a new stake in Athersys during the second quarter valued at approximately $394,000. Schwab Charles Investment Management Inc. lifted its stake in Athersys by 50.9% during the second quarter. Schwab Charles Investment Management Inc. now owns 250,900 shares of the biopharmaceutical company’s stock valued at $495,000 after purchasing an additional 84,600 shares during the last quarter. BlackRock Inc. lifted its stake in Athersys by 22.4% during the second quarter. BlackRock Inc. now owns 6,000,666 shares of the biopharmaceutical company’s stock valued at $11,821,000 after purchasing an additional 1,097,520 shares during the last quarter. Renaissance Technologies LLC lifted its stake in Athersys by 21.3% during the second quarter. Renaissance Technologies LLC now owns 439,900 shares of the biopharmaceutical company’s stock valued at $867,000 after purchasing an additional 77,100 shares during the last quarter. Finally, Millennium Management LLC lifted its stake in Athersys by 377.6% during the second quarter. Millennium Management LLC now owns 457,667 shares of the biopharmaceutical company’s stock valued at $902,000 after purchasing an additional 361,835 shares during the last quarter. 19.55% of the stock is owned by institutional investors and hedge funds.

NASDAQ ATHX opened at $1.45 on Wednesday. Athersys has a 52 week low of $1.29 and a 52 week high of $3.09. The stock has a market capitalization of $221.12 million, a price-to-earnings ratio of -5.00 and a beta of 0.03.

Athersys (NASDAQ:ATHX) last posted its earnings results on Tuesday, November 6th. The biopharmaceutical company reported ($0.07) EPS for the quarter, topping the consensus estimate of ($0.08) by $0.01. Athersys had a negative net margin of 108.83% and a negative return on equity of 58.74%. The firm had revenue of $2.32 million during the quarter, compared to analysts’ expectations of $1.80 million. On average, sell-side analysts forecast that Athersys will post -0.19 earnings per share for the current year.

About Athersys

Athersys, Inc, a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions.

See Also: What is a put option?

Get a free copy of the Zacks research report on Athersys (ATHX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Athersys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athersys and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit